BridgeBio Pharma, Inc. · Brief

Next report

71 days

Jan 11 · after closeest.Q4 FY26

Expected move

±14.1%implied · straddle

64.3785.53

spot 74.95exp Jan 15ATM strike 75ATM straddle 12.45IV 46%

Oct 30 closeprovisional

Expected move

8 reportsHistory

0 of 8≥ implied

Apr 29 '25±10.8%▲+5.33%×0.49

Aug 5 '25±11.5%▼−8.94%×0.78

Q3 FY25±11.7%▼−4.88%×0.42

Jan 12 '26±4.6%▲+2.95%×0.64

Q1 FY26±10.6%▼−2.59%×0.24

May 7 '26±7.4%▼−0.09%×0.01

Q2 FY26±6.9%▼−1.15%×0.17

Q3 FY26±10.2%▲+5.97%×0.58

quarterimplied−15%0+15%realized×

Q3 FY26±10.2%▲+5.97%×0.58

Q2 FY26±6.9%▼−1.15%×0.17

May '26±7.4%▼−0.09%×0.01

Q1 FY26±10.6%▼−2.59%×0.24

Jan '26±4.6%▲+2.95%×0.64

Q3 FY25±11.7%▼−4.88%×0.42

2 older reports

Aug '25±11.5%▼−8.94%×0.78

Apr '25±10.8%▲+5.33%×0.49

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Jan 11 report · est.

—

BBIO report session

No linked exposure.

Oct 29impliedImplied move: ±10.2% into Oct 29 earnings (Oct 29 close).Source

Oct 14impliedImplied move: ±9.3% into Oct 28 earnings (Oct 14 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.